Table 4.
Univariable and multivariable logistic regression analysis with respect to MRI morphologic tumor response at follow-up
| Variables | Univariable model | Multivariable model | ||
|---|---|---|---|---|
| Demographics | OR | Sign. | OR | Sign. |
| Sex (male) | 0.70 | 0.59 | ||
| Age (years) > 70 | 0.91 | 0.85 | ||
| Liver disease | ||||
| BCLC tumor stage (C vs. B) | 0.31 | 0.16 | ||
| Hepatitis (yes/no) | 1.93 | 0.37 | ||
| Cirrhosis (yes/no) | 1.03 | 0.96 | ||
| Previous treatments | ||||
| TKI (yes/no) | 0.44 | 0.23 | ||
| Resection (yes/no) | 0.56 | 0.41 | ||
| TACE (yes/ no) | 2.19 | 0.35 | ||
| Ablation (yes/no) | 4.30 | 0.18 | ||
| Radioembolization approach | ||||
| Sequential lobar therapy (yes/no) | 2.31 | 0.25 | 5.8 | 0.07 |
| Dose reduction (yes/no) | 0.73 | 0.68 | ||
| Tumor characterization | ||||
| Ln TTV (in mL) | 0.52 | 0.03 | 0.4 | 0.01 |
| Ln ETV (in mL) | 0.73 | 0.23 | ||
| ETV/TTV | 4.39 | 0.15 | ||
| ETV/TTV > 50% | 3.41 | 0.07 | 6.3 | 0.02 |
| Hepatopulmonary shunt in % | 1.08 | 0.23 | 1.3 | 0.01 |
| Performance of the multivariable model | ||||
| Significance | p = 0.001 | |||
| Nagelkerke’s pseudo-R2 (range, competing models) | 0.44 (0.30-0.44) | |||
BCLC, Barcelona Clinic Liver Cancer stage; ETV, enhancing tumor volume; HR, hazard ratio; Ln, natural logarithm; ml, milliliter; Sign., significance; TACE, transarterial chemoembolization; TKI, tyrosine kinase inhibitor; TTV, total tumor volume